Corporate$NRXP8:30 AM ETdeveloping · v2

NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine ahead of FDA goal date

By BORSA NewsroomPublished Oct 19, 2026, 8:30 AM EDTUpdated Oct 19, 2026, 8:33 AM EDT

NRx Pharmaceuticals (NRXP) announced completion of three process validation lots and two-year room-temperature stability data for its preservative-free ketamine. Commercial supply is on hand pending ANDA approval. The FDA GDUFA goal date is November 10, 2026.

Sentimentbullish 75

Bullish · 75 of 100

Impact60

medium · sector-wide

Confidence90%

high confidence · 2 wires

Eventdeveloping

v2 · alerted to followers

WHAT WE KNOW

Three Process Validation lots completed under commercial conditions.